Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRANSPEPTID

Financiado

Developing new antibiotic peptides targeting ESKAPE bacterial trans- translation

Antimicrobial resistance (AMR) poses a major threat to human health around the world. The AMR crisis has emerged as one of the leading public health threats of the 21st century. This global crisis is due to the fact that bacteria... ver más

31/08/2027

UNIVREN

212K€

Presupuesto del proyecto: 212K€

Líder del proyecto

UNIVERSITE DE RENNES No se ha especificado una descripción o un objeto social para esta compañía.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-06

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

2 Participantes

UNIVREN

211.75K€ | Lider

CNRS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MAREE Mechanisms of Antibiotic Recalcitrance in ESKAPE pathogens 196K€ Cerrado

PID2021-122705OB-I00 REDIRECCIONANDO EL DESCUBRIMIENTO DE ANTIMICROBIALES Y UTILI... 169K€ Cerrado

PLEC2022-009507 Caseinolytic Protease P (ClpP) Agonists: Small Molecules wit... 83K€ Cerrado

NAfrAM Novel antibiotics from Antarctic microbes 190K€ Cerrado

PID2020-113521RB-I00 APROXIMACIONES BASADAS EN LA FISIOLOGIA Y LA EVOLUCION PARA... 278K€ Cerrado

BFU2017-90030-P APUNTANDO A LA RESISTENCIA A ANTIBIOTICOS: BASES ESTRUCTURAL... 387K€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2024-05-06
Fecha Fin: 2027-08-31

Líder del proyecto

UNIVERSITE DE RENNES No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 212K€

Descripción del proyecto Antimicrobial resistance (AMR) poses a major threat to human health around the world. The AMR crisis has emerged as one of the leading public health threats of the 21st century. This global crisis is due to the fact that bacteria share and increasingly develop new resistance mechanisms as a consequence of the misuse of antibiotics, as well as a lack of new drug development. To combat this crisis, we need new classes of antibiotics, and most importantly, against new targets. It is therefore crucial to identify new molecular processes that can be targeted. Ideally, these should be: i) conserved among all pathogenic ESKAPE bacteria; ii) indispensable to bacterial survival or at least its fitness; iii) sufficiently variable that different species can be distinguished from each other; iv) absent in eukaryotes; v) not targeted by current antibiotics; vi) unrelated to existing AMR mechanisms; and finally, vii) reproducible in non- hazardous in vitro experiments. In this quest, trans-translation appears to be a perfect candidate. Development of new antibiotics that target trans-translation from multidrug resistant ESKAPE pathogens will be addressed in this project (TRANSPEPTID). We will use engineer antimicrobial peptides based on the C- terminal tails of SmpB proteins from ESPAKE pathogens with the propose to compete with endogenous SmpB, and in turn to inhibit trans-translation. The project is organized in three main objectives that will constitute three major breakthroughs in the field: (OB1) Optimization and characterization of designed peptides in ESKAPE pathogens, (OB2) Biophysical analysis of selected peptides in target ESKAPE pathogens, and (OB3) Determination of the high- resolution structures of the complexes between the peptides and their molecular targets by cryo-EM. Since TRANSPEPTID is a multidisciplinay project that embraces both fundamental and applied science, it will contribute significantly to strength the research and training profile of the researcher

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores